Ranolazine: Uses, Dosage, Side Effects & Brands | MedexInfo

Ranolazine

Rx Only

Generic NameRanolazine

Therapeutic ClassAntianginal Agent

Common Dose500–1000 mg twice daily

Max / 24h2000 mg

PregnancyCategory C

Indications ▼

Chronic stable angina

Adjunct therapy when beta-blockers, calcium channel blockers, or nitrates are insufficient

Mechanism & Pharmacokinetics ▼

Mechanism: Inhibits late phase sodium current (INa) in cardiac myocytes, reducing intracellular sodium and calcium overload, improving myocardial relaxation and oxygen efficiency.

Pharmacokinetics: Well absorbed orally; peak plasma concentration in 2–5 hours; metabolized mainly via CYP3A4 and partially CYP2D6; elimination half-life ~7 hours; excreted via urine and feces.

Dosage & Administration ▼

Patient Category	Recommended Dose	Max / 24h
Adults (Initial)	500 mg twice daily	2000 mg
Adults (Maintenance)	May increase to 1000 mg twice daily	2000 mg
Elderly	Use cautiously; monitor renal function	2000 mg
Renal / Hepatic Impairment	Use with caution; avoid in severe hepatic impairment	2000 mg

Note: Swallow extended-release tablets whole; do not crush or chew. Can be taken with or without food.

Side Effects ▼

Common: Dizziness, headache, constipation, nausea

Occasional: Palpitations, hypotension

Serious: QT interval prolongation

Contraindications ▼

Clinically significant hepatic impairment

Concomitant use with strong CYP3A inhibitors (e.g., ketoconazole)

Known hypersensitivity to ranolazine

Drug Interaction ▼

Strong CYP3A inhibitors increase plasma levels

CYP3A inducers reduce effectiveness

May increase plasma concentration of digoxin and simvastatin

Use cautiously with other QT-prolonging drugs

Pregnancy & Lactation ▼

Category C; use only if potential benefit justifies risk

Breastfeeding safety not established; use caution

Clinical / Research Summary ▼

Improves exercise tolerance and reduces angina frequency

Does not significantly affect heart rate or blood pressure

Useful add-on therapy in patients inadequately controlled with conventional antianginal drugs

Requires monitoring for QT prolongation risk

Patient Counseling Points ▼

Do not crush or chew extended-release tablets

Report dizziness or fainting

Avoid grapefruit products

Continue other cardiac medications as prescribed

Storage & Handling ▼

Store below 30°C

Keep away from moisture and light

Brand Names (Bangladesh & Global) ▼

Bangladesh:

Antogin ER® 500 mg Ralozine SR® 500 mg Ranocor ER® 500 mg Ranola® 500 mg Ranolin XR® 500 mg Ranovent ER® 500 mg Ranozex® 500 mg Renexin XR® 500 mg

Global:

Ranexa® Ranolazine (Generic)

Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice.

Reference Hubs:

• Drug Class: Antianginal Agents • Condition: Chronic Stable Angina • Clinical Evidence & Trials